158 related articles for article (PubMed ID: 35486326)
1. Dispositions and Causality Assessment in Pharmacovigilance: Proposing the Dx3 Approach for Assessing Causality with Small Data Sets.
Anjum RL; Chandler RE; Rocca E
Pharmaceut Med; 2022 Jun; 36(3):153-161. PubMed ID: 35486326
[TBL] [Abstract][Full Text] [Related]
2. Leveraging Machine Learning to Facilitate Individual Case Causality Assessment of Adverse Drug Reactions.
Cherkas Y; Ide J; van Stekelenborg J
Drug Saf; 2022 May; 45(5):571-582. PubMed ID: 35579819
[TBL] [Abstract][Full Text] [Related]
3. Causality assessment in pharmacovigilance: The French method and its successive updates.
Miremont-Salamé G; Théophile H; Haramburu F; Bégaud B
Therapie; 2016 Apr; 71(2):179-86. PubMed ID: 27080836
[TBL] [Abstract][Full Text] [Related]
4. Sorting Through the Safety Data Haystack: Using Machine Learning to Identify Individual Case Safety Reports in Social-Digital Media.
Comfort S; Perera S; Hudson Z; Dorrell D; Meireis S; Nagarajan M; Ramakrishnan C; Fine J
Drug Saf; 2018 Jun; 41(6):579-590. PubMed ID: 29446035
[TBL] [Abstract][Full Text] [Related]
5. Towards Automating Adverse Event Review: A Prediction Model for Case Report Utility.
Muñoz MA; Dal Pan GJ; Wei YJ; Delcher C; Xiao H; Kortepeter CM; Winterstein AG
Drug Saf; 2020 Apr; 43(4):329-338. PubMed ID: 31912439
[TBL] [Abstract][Full Text] [Related]
6. Contribution of Causality Assessment for an Automated Detection of Safety Signals: An Example Using the French Pharmacovigilance Database.
Berbain T; Pariente A; Miremont-Salamé G; Grandvuillemin A; Micallef J; Chouchana L; Benkebil M; Théophile H;
Drug Saf; 2020 Mar; 43(3):243-253. PubMed ID: 31974775
[TBL] [Abstract][Full Text] [Related]
7. Drug-induced liver injury in Switzerland: an analysis of drug-related hepatic disorders in the WHO pharmacovigilance database VigiBase from 2010 to 2020.
Ortland I; Mirjalili M; Kullak-Ublick GA; Peymani P
Swiss Med Wkly; 2021 May; 151():w20503. PubMed ID: 34000058
[TBL] [Abstract][Full Text] [Related]
8. MOdified NARanjo Causality Scale for ICSRs (MONARCSi): A Decision Support Tool for Safety Scientists.
Comfort S; Dorrell D; Meireis S; Fine J
Drug Saf; 2018 Nov; 41(11):1073-1085. PubMed ID: 29876835
[TBL] [Abstract][Full Text] [Related]
9. Key elements in adverse drug interaction safety signals: an assessment of individual case safety reports.
Strandell J; Norén GN; Hägg S
Drug Saf; 2013 Jan; 36(1):63-70. PubMed ID: 23315297
[TBL] [Abstract][Full Text] [Related]
10. Individual Case Safety Report Replication: An Analysis of Case Reporting Transmission Networks.
van Stekelenborg J; Kara V; Haack R; Vogel U; Garg A; Krupp M; Gofman K; Dreyfus B; Hauben M; Bate A
Drug Saf; 2023 Jan; 46(1):39-52. PubMed ID: 36565374
[TBL] [Abstract][Full Text] [Related]
11. Development of a multivariate prediction model to identify individual case safety reports which require clinical review.
Gosselt HR; Bazelmans EA; Lieber T; van Hunsel FPAM; Härmark L
Pharmacoepidemiol Drug Saf; 2022 Dec; 31(12):1300-1307. PubMed ID: 36251280
[TBL] [Abstract][Full Text] [Related]
12. Comparison of three methods (consensual expert judgement, algorithmic and probabilistic approaches) of causality assessment of adverse drug reactions: an assessment using reports made to a French pharmacovigilance centre.
Théophile H; Arimone Y; Miremont-Salamé G; Moore N; Fourrier-Réglat A; Haramburu F; Bégaud B
Drug Saf; 2010 Nov; 33(11):1045-54. PubMed ID: 20925441
[TBL] [Abstract][Full Text] [Related]
13. Causality assessment of adverse drug reaction reports using an expert-defined Bayesian network.
Rodrigues PP; Ferreira-Santos D; Silva A; Polónia J; Ribeiro-Vaz I
Artif Intell Med; 2018 Sep; 91():12-22. PubMed ID: 30077492
[TBL] [Abstract][Full Text] [Related]
14. A Risk-Based Approach for Safety Case Follow-up of Adverse Event Reports in Pharmacovigilance.
Vemula GK; Badale P; Mavrogenis P; Lalande-Luesink I; Borkowski M; Lewis DJ
Adv Ther; 2024 Jan; 41(1):82-91. PubMed ID: 37919600
[TBL] [Abstract][Full Text] [Related]
15. An Evaluation of Postmarketing Reports with an Outcome of Death in the US FDA Adverse Event Reporting System.
Marwitz K; Jones SC; Kortepeter CM; Dal Pan GJ; Muñoz MA
Drug Saf; 2020 May; 43(5):457-465. PubMed ID: 31981082
[TBL] [Abstract][Full Text] [Related]
16. Safety Concerns Reported by Patients Identified in a Collaborative Signal Detection Workshop using VigiBase: Results and Reflections from Lareb and Uppsala Monitoring Centre.
Watson S; Chandler RE; Taavola H; Härmark L; Grundmark B; Zekarias A; Star K; van Hunsel F
Drug Saf; 2018 Feb; 41(2):203-212. PubMed ID: 28933055
[TBL] [Abstract][Full Text] [Related]
17. A Feasibility Study of Drug-Drug Interaction Signal Detection in Regular Pharmacovigilance.
Hult S; Sartori D; Bergvall T; Hedfors Vidlin S; Grundmark B; Ellenius J; Norén GN
Drug Saf; 2020 Aug; 43(8):775-785. PubMed ID: 32681439
[TBL] [Abstract][Full Text] [Related]
18. A tailor-made approach for causality assessment for ADR reports on drugs and vaccines.
Oosterhuis I; Zweers P; Rümke H; Muller-Hansma A; van Puijenbroek EP
Pharmacoepidemiol Drug Saf; 2019 Apr; 28(4):544-550. PubMed ID: 30168222
[TBL] [Abstract][Full Text] [Related]
19. Toward Kidney-Specific Causality Assessment Tool.
Kaya M; Duru M; Gulmez SE
Clin Ther; 2022 Jul; 44(7):e59-e75. PubMed ID: 35725506
[TBL] [Abstract][Full Text] [Related]
20. Pharmacovigilance in ophthalmology in Switzerland: an analysis of the most frequently reported ocular adverse drug reactions within the last 25 years.
Karrer JE; Giovannoni L; Kullak-Ublick GA; Weiler S
Swiss Med Wkly; 2019 Jun; 149():w20085. PubMed ID: 31256417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
